Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial
about
The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization propertiesNicotine receptors and depression: revisiting and revising the cholinergic hypothesisBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved TherapeuticsAntidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a reviewReview of pharmacological treatment in mood disorders and future directions for drug development.Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptorsThe effects of drugs on human models of emotional processing: an account of antidepressant drug treatmentNeurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuseThe Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?Innovative solutions to novel drug development in mental healthMaintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapyScopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.Brain arousal regulation as response predictor for antidepressant therapy in major depression.Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.Experimental medication treatment approaches for depression.Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.Down-regulation of cholinergic signaling in the habenula induces anhedonia-like behavior.A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder.Ketamine as a potential treatment for suicidal ideation: a systematic review of the literatureNeuroplasticity and major depression, the role of modern antidepressant drugsRecent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.Stuck in a rut: rethinking depression and its treatment.How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy.Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.Beyond serotonin: newer antidepressants in the future.Scopolamine produces larger antidepressant and antianxiety effects in women than in men.Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.Elevated Hippocampal Cholinergic Neurostimulating Peptide precursor protein (HCNP-pp) mRNA in the amygdala in major depression.Signaling pathways underlying the rapid antidepressant actions of ketamineRodent models of treatment-resistant depression.Advances in the Management of Treatment-Resistant DepressionThe prominent role of stimulus processing: cholinergic function and dysfunction in cognition.Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.Spine synapse remodeling in the pathophysiology and treatment of depression.Brain-derived neurotrophic factor and neuropsychiatric disorders.Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine
P2860
Q24633511-7193DF1C-B231-4A59-A45B-6C3749060E5CQ24634536-F1AFA851-8A45-4738-8FF7-072035B83FCDQ26782993-92ABE23E-4B43-4949-9C8F-13F588D42DF1Q26782997-91995796-80DF-4EA2-B883-E4A0B0916085Q26822244-EE46C3A3-94B0-4391-9346-6BE815F102CAQ26853509-552343F3-C484-4259-A0E9-3C6AE3F11A04Q27308009-FC0BCD08-6A82-4A7D-8FED-2183E3B781E9Q28072345-6367A983-F383-481F-B5ED-549A0B70DF6EQ28076105-DFF47786-6043-432A-B5D6-B9B3239DE232Q28082434-01AAA8E0-3932-4B20-8682-5B0599E1BAE6Q28677399-33EE6408-09CC-4D38-96A1-40C10C836FF1Q30432684-1020B118-DA8E-4C7E-9BAA-D8BD347B76F6Q30544800-58220385-479E-47D9-9EE9-6744086B9AECQ30842926-5609C658-506C-41FA-92D3-B146C45EC6FDQ33604879-3E21D5CF-E42B-4B1D-9C34-5B81C25E0347Q33635577-6682BC55-AD42-46EB-8A30-ED36AC4869AFQ33647744-34F42AC7-76DA-4501-8D93-CA9DFCA4B501Q33678595-F7E92116-207F-46AF-8B6F-030D2E00FFA3Q33751814-D12CCA25-782A-4F13-9956-AC568822E1C9Q34043478-780A9D1D-D701-4AC5-84EF-26244E58F7DDQ34381499-2DA01A50-9A28-4737-820F-C9B41DF487B1Q34394190-EE0BA7A7-96A4-45A1-972C-B61C672276CAQ34459160-21534D17-C023-414C-A5C3-168610D7B2D6Q34511676-681B8B5C-D37D-482D-83D6-23CDDDD397A5Q34512818-95EE8009-CBE3-40D4-91CF-9E4843481080Q34557706-013F6897-E5F7-4D7E-B359-EEF0E2651D34Q34660507-200F1332-8AC4-4F78-BFA8-1EEAB8AD4772Q34661281-3C8A899E-5BDC-4102-98E1-314C953F938BQ34766451-4DCEB22A-9501-4647-97DD-6C11DC836EE3Q35054681-80AAA10B-09BE-4257-A75D-E8DDB6ABD45BQ35287782-FDBCF435-ED6F-4132-9147-82F659CA37F3Q35375293-2E55B33B-A720-4826-A043-DBD4C7520D6FQ35580361-7E28095B-90CD-4859-B591-4308757E2050Q35580600-93CCC2D6-2232-4854-9C16-6876673BD65AQ35689769-9C23F6A5-2EC1-4D0A-B444-19841BFCC89DQ35699233-3243262F-8576-4D2D-AF34-96CA15AC2988Q35738694-7663294C-F1B3-40EC-A75A-B18379E92593Q35836787-ED63D3CB-3F04-4CF1-B6AA-FA4FC1CFF5F4Q35847085-DFF6F589-7F85-428D-83F6-19FD5889AA9FQ36064491-921A1933-17F7-4CD9-B447-55156D66D26A
P2860
Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Replication of scopolamine's a ...... cebo-controlled clinical trial
@ast
Replication of scopolamine's a ...... cebo-controlled clinical trial
@en
type
label
Replication of scopolamine's a ...... cebo-controlled clinical trial
@ast
Replication of scopolamine's a ...... cebo-controlled clinical trial
@en
prefLabel
Replication of scopolamine's a ...... cebo-controlled clinical trial
@ast
Replication of scopolamine's a ...... cebo-controlled clinical trial
@en
P2860
P1476
Replication of scopolamine's a ...... cebo-controlled clinical trial
@en
P2093
Maura L Furey
P2860
P304
P356
10.1016/J.BIOPSYCH.2009.11.021
P407
P577
2010-01-15T00:00:00Z